Which has the lower trailing P/E, BIIB or DXCM?

BIIB has the lower trailing P/E: BIIB trades at 21.43 and DXCM at 31.35. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BIIB or DXCM?

Over the past five years, DXCM grew revenue faster — BIIB at a -4.80% CAGR versus DXCM at 18.91%.

Is BIIB or DXCM more profitable?

DXCM runs the higher net margin — BIIB at 13.92% versus DXCM at 19.31%.

How have BIIB and DXCM total returns compared?

Over the past 10 years, BIIB delivered -3.46% and DXCM delivered 12.96% annualized total return. Past performance doesn't predict future results.

Biogen Inc. (BIIB) vs DexCom, Inc. (DXCM)

A side-by-side comparison of Biogen Inc. and DexCom, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 28, 2026. Differences are shown without an overall score or investment verdict.

BIIB

Biogen Inc.

$30.36B

$205.61HealthcareDelayed quote: Jul 28, 2026, 4:00 PM EDT

DXCM

DexCom, Inc.

$28.88B

$74.85HealthcareDelayed quote: Jul 28, 2026, 4:00 PM EDT

Total return — BIIB vs DXCM

growth of $100 · dividends reinvested · last 21y

BIIB +463.7%DXCM +2474.8%DXCM compounded faster

BIIB DXCM

BIIB vs DXCM: by the numbers

•BIIB is the larger company ($30.36B vs $28.88B market cap).
•BIIB trades at the lower trailing earnings multiple (21.43 vs 31.35 P/E), one valuation lens rather than an overall verdict.
•DXCM converts more revenue to profit (19.31% vs 13.92% net margin).
•DXCM grew revenue faster over the past five years (18.91% vs -4.80% CAGR).

Metrics side by side

Valuation

Metric	BIIB	DXCM
P/E ratio	21.43	31.35
Forward P/E	15.71	28.29
P/S ratio	3.01	5.99
P/B ratio	1.59	9.77
PEG ratio	N/A	0.67
EV / EBITDA	13.53	22.55
FCF yield	8.83%	4.95%

Profitability

Metric	BIIB	DXCM
Gross margin	69.77%	61.84%
Operating margin	15.65%	21.45%
Net margin	13.92%	19.31%
ROE	7.36%	31.47%
ROIC	6.62%	16.61%

Growth (annualized)

Metric	BIIB	DXCM
Revenue CAGR (5Y)	-4.80%	18.91%
EPS CAGR (5Y)	-18.67%	10.31%
FCF CAGR (5Y)	-3.59%	43.37%
Total return CAGR (5Y)	-9.48%	-8.02%

Frequently asked

Which has the lower trailing P/E, BIIB or DXCM?: BIIB has the lower trailing P/E: BIIB trades at 21.43 and DXCM at 31.35. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BIIB or DXCM?: Over the past five years, DXCM grew revenue faster — BIIB at a -4.80% CAGR versus DXCM at 18.91%.
Is BIIB or DXCM more profitable?: DXCM runs the higher net margin — BIIB at 13.92% versus DXCM at 19.31%.
How have BIIB and DXCM total returns compared?: Over the past 10 years, BIIB delivered -3.46% and DXCM delivered 12.96% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BIIB analysis Full DXCM analysis Interactive comparison tool

Dig into the metrics

Biogen P/E ratio DexCom P/E ratio Biogen dividend yield DexCom dividend yield Biogen ROE DexCom ROE Biogen operating margin DexCom operating margin Biogen revenue growth DexCom revenue growth Biogen free cash flow DexCom free cash flow

Biogen & DexCom appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 28, 2026.